<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03504488</url>
  </required_header>
  <id_info>
    <org_study_id>BA3021-001</org_study_id>
    <nct_id>NCT03504488</nct_id>
  </id_info>
  <brief_title>CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head &amp; Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)</brief_title>
  <official_title>A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioAtla, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioAtla, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety,&#xD;
      tolerability, PK, immunogenicity, and antitumor activity of BA3021, a conditionally active&#xD;
      biologic (CAB) ROR2-targeted antibody drug conjugate (CAB-ROR2-ADC) BA3021 in patients with&#xD;
      advanced solid tumors.&#xD;
&#xD;
      This study will consist of a dose escalation phase and a dose expansion phase with BA3021 in&#xD;
      Phase 1. Phase 2 will study BA3021 alone or in combination with a PD-1 inhibitor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Safety Profile</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Assess dose limiting toxicity as defined in the protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Safety Profile</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Assess maximum tolerated dose as defined in the protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 and 2: Safety Profile</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Frequency and severity of AEs and/or SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Confirmed Objective Response Rate (ORR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Proportion of patients who achieve a confirmed CR or PR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Pharmacokinetics</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Plasma concentrations of ADC, total antibody and MMAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Pharmacokinetics</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Pharmacokinetics</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Area under the plasma concentration versus time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Confirmed Objective Response Rate (ORR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Proportion of patients who achieve a confirmed CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Immunogenicity</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The number and percentage of patients who develop detectable anti-drug antibodies (ADAs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Duration of response (DOR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time from the first documented OR until the first documented disease progression or death (due to any cause), whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Progression-free survival (PFS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time from the first dose of IP until the first documentation of disease progression or death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Best overall response (OR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>All post-baseline disease assessments that occur prior to the initiation of subsequent anticancer therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Disease control rate (DCR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Proportion of patients with a best overall response of confirmed CR, confirmed PR, or stable disease (SD) ≥ 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Time to response (TTR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time from the first dose of investigational product until the first documentation of OR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Overall survival (OS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time from the first dose of BA3021 treatment until death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Tumor size</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Percent change from baseline in tumor size</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Monotherapy - CAB-ROR2-ADC (BA3021) alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BA3021 alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAB-ROR2-ADC (BA3021) with PD-1 inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAB-ROR2-ADC</intervention_name>
    <description>Conditionally active biologic anti-ROR2 antibody drug conjugate</description>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_label>Monotherapy - CAB-ROR2-ADC (BA3021) alone</arm_group_label>
    <other_name>BA3021</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PD-1 inhibitor</intervention_name>
    <description>PD-1 inhibitor</description>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed locally advanced&#xD;
             unresectable or metastatic solid tumor and have failed all available standard of care&#xD;
             (SoC) therapy and for whom no curative therapy is available or who are not eligible,&#xD;
             intolerant to or refuse standard therapy.&#xD;
&#xD;
          -  Patients must have measurable disease.&#xD;
&#xD;
          -  For the dose expansion phase: Patients with locally advanced unresectable or&#xD;
             metastatic, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC)&#xD;
             and soft tissue sarcoma (STS)&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Adequate liver function&#xD;
&#xD;
          -  Adequate hematological function&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Life expectancy of at least three months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients must not have clinically significant cardiac disease.&#xD;
&#xD;
          -  Patients must not have known non-controlled CNS metastasis.&#xD;
&#xD;
          -  Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as&#xD;
             wellas known or suspected allergy or intolerance to any agent given during this study.&#xD;
&#xD;
          -  Patients must not have had major surgery within 4 weeks before first BA3021&#xD;
             administration.&#xD;
&#xD;
          -  Patients must not have had prior therapy with a conjugated or unconjugated auristatin&#xD;
             derivative/vinca-binding site targeting payload.&#xD;
&#xD;
          -  Patients must not have known human immunodeficiency virus (HIV) infection, active&#xD;
             hepatitis B and/or hepatitis C.&#xD;
&#xD;
          -  Patients must not be women who are pregnant or breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Martin</last_name>
    <role>Study Director</role>
    <affiliation>BioAtla, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hazel Buncab</last_name>
    <phone>858-263-1598</phone>
    <phone_ext>8582631598</phone_ext>
    <email>hbuncab@bioatla.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji Hwan Lee</last_name>
    <phone>858-286-7702</phone>
    <email>jlee@bioatla.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavani Chalasani, MD</last_name>
      <phone>520-626-0191</phone>
      <email>pavanic@email.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Pavani Chalasani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedar-Sinai</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Menendez</last_name>
      <phone>310-231-2184</phone>
      <email>rmenendez@theangelesclinic.org</email>
    </contact>
    <contact_backup>
      <last_name>Linda Ford, PA-C</last_name>
      <phone>310-285-7268</phone>
      <email>Linda.ford@cshs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Omid Hamid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Medina, MD</last_name>
      <phone>303-266-3764</phone>
      <email>theresa.medina@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rebeca Elizondo</last_name>
      <phone>720-848-4288</phone>
      <email>rebeca.elizondo@cuanschutz.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Teresa Medina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at Health One</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Falchook, MD</last_name>
      <phone>720-754-2610</phone>
      <email>gerald.falchook@scresaerch.net</email>
    </contact>
    <contact_backup>
      <last_name>Susan Hall</last_name>
      <phone>720-754-2610</phone>
      <email>Susan.Hall3@sarahcannon.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gerald Falchook, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Wheeler</last_name>
      <phone>646-888-1385</phone>
      <email>wheelers@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Bella Pinque</last_name>
      <phone>646-888-1394</phone>
      <email>PinqueI@mskcc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Bill Tap</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Chapman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Andrews</last_name>
      <phone>813-745-3553</phone>
      <email>Jacqueline.Andrews@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Mihaela Druta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andres Saltos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Care of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fadi Braiteh, MD</last_name>
      <phone>702-952-3400</phone>
      <email>Fadi.Braiteh@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Fadi Braiteh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Swathi Balaji</last_name>
      <phone>212-304-5548</phone>
      <email>sb4461@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Morgan Bryant</last_name>
      <phone>212-342-9004</phone>
      <email>mb4695@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Ingham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Kettler</last_name>
      <phone>336-716-4760</phone>
      <email>jkettler@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nikolas Soetermans</last_name>
      <phone>336-713-5865</phone>
      <email>nsoeterm@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lowell Hart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyaw Thein, MD</last_name>
      <email>theink@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Andrzej Stadnik</last_name>
      <phone>503-494-2636</phone>
      <email>stadnik@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kyaw Thein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Burris, MD</last_name>
      <email>Howard.Burris@SarahCannon.com</email>
    </contact>
    <contact_backup>
      <last_name>Leigh Bumpous</last_name>
      <phone>615-748-0767</phone>
      <email>Leigh.Bumpous@SarahCannon.com</email>
    </contact_backup>
    <investigator>
      <last_name>Howard Burris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoko Yamamura</last_name>
      <phone>713-792-9869</phone>
      <email>yyamamur@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Siqing Fu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah - Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mia Klonsky</last_name>
      <phone>801-581-5260</phone>
      <email>Mia.Klonsky@hci.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Lewary</last_name>
      <email>Ashley.Leary@hci.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joanne Jeter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 12, 2018</study_first_submitted>
  <study_first_submitted_qc>April 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2018</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

